The Centre For Therapeutic Target Validation – An Open Innovation Collaboration
Jessica Vamathevan,
Centre for Therapeutic Target Validation (CTTV) Operations Director,
GlaxoSmithKline
The CTTV is a pioneering public-private research initiative between Biogen, the European Bioinformatics Institute, GSK and the Wellcome Trust Sanger Institute to harness the power of ‘big data’ and genome sequencing to improve the success rate for discovering new medicines. The CTTV aims to generate evidence on the biological validity of therapeutic targets and provide an initial assessment of the likely effectiveness of pharmacological intervention on these targets, using genome-scale experiments and analysis. The CTTV aims to provide an R&D framework that applies to all aspects of human disease, and to share its data openly with the scientific community. Using an user-centred design process, and tested extensively through usability workshops, interviews and reviews with a panel of scientists the CTTV recently launched to the scientific community data a data integration and visualization platform that provides evidence about the association of potential drug targets with disease. The platform is designed to enable biomedical researchers who need to discover a biological target for a new therapy to identify and prioritise targets for follow up. Further development of the platform aims to incorporate other data types plus data from the CTTV experimental projects with the aim of providing a world-class scalable resource that serves to answer both quantitatively and qualitatively the fundamental questions in target validation.
|
|
